These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12812383)

  • 1. Value of thromboelastography in the assessment of platelet function.
    Bowbrick VA; Mikhailidis DP; Stansby G
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):137-42. PubMed ID: 12812383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA; Khurana S; Forsythe MS
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
    Mousa SA; Bozarth JM; Seiffert D; Feuerstein GZ
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):165-71. PubMed ID: 15795533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?
    Bailey LA; Sistino JJ; Uber WE
    J Extra Corpor Technol; 2005 Mar; 37(1):43-7. PubMed ID: 15804156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
    Bertram U; Moser M; Peter K; Kuecherer HF; Bekeredjian R; Straub A; Nordt TK; Bode C; Ruef J
    J Thromb Thrombolysis; 2002 Dec; 14(3):197-203. PubMed ID: 12913399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Voss R
    J Thromb Thrombolysis; 2001 Oct; 12(2):129-39. PubMed ID: 11729364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation.
    Yomo T; Serna DL; Powell LL; Wang D; Wilson SE; Ishimaru S; Chen JC
    Artif Organs; 2000 May; 24(5):355-61. PubMed ID: 10848676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
    Gremmel T; Koppensteiner R; Panzer S
    PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.
    Alam M; Gonzalez R; Delarosa A; Bobek J; Dokainish H; Lakkis N
    Am Heart Hosp J; 2009; 7(1):17-20. PubMed ID: 19742428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
    Fisher I; Robinson P; Ritter JM
    Br J Clin Pharmacol; 1999 Aug; 48(2):197-9. PubMed ID: 10417496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
    Naimushin YA; Mazurov AV
    Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban.
    Otto C; Baumann M; Schreiner T; Bartsch G; Borberg H; Schwandt P; Schmid-Schönbein H
    Eur J Ultrasound; 2001 Dec; 14(2-3):157-66. PubMed ID: 11704433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography.
    Mousa SA; Forsythe MS
    Thromb Res; 2001 Oct; 104(1):49-56. PubMed ID: 11583738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.